What Is Ibrutinib? Uses, Dosage, and What You Need to Know in 2026

What Is Ibrutinib?

Ibrutinib is a prescription oral medication that belongs to a class of drugs called Bruton's tyrosine kinase (BTK) inhibitors, used to treat certain types of blood cancers and chronic graft-versus-host disease.

Sold under the brand name Imbruvica, Ibrutinib is manufactured by Pharmacyclics LLC (an AbbVie company) and Janssen Biotech, Inc. It was first approved by the FDA in 2013, making it the first BTK inhibitor to reach the market. Ibrutinib is not a controlled substance.

This guide covers everything patients need to know about Ibrutinib in 2026 — what it treats, how to take it, who should avoid it, and what it costs.

What Is Ibrutinib Used For?

Ibrutinib is FDA-approved to treat the following conditions:

Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

CLL and SLL are closely related blood cancers that affect white blood cells called lymphocytes. Ibrutinib can be used as a first-line treatment or after other treatments have failed. It is one of the most widely prescribed medications for CLL.

Waldenström's Macroglobulinemia (WM)

WM is a rare type of non-Hodgkin lymphoma that causes the body to produce abnormal antibodies. Ibrutinib is approved for WM treatment.

Chronic Graft-Versus-Host Disease (cGVHD)

cGVHD is a condition that can develop after a stem cell or bone marrow transplant, where donor cells attack the patient's body. Ibrutinib is approved for cGVHD in adults and children aged 12 and older who have not responded to at least one prior line of therapy.

Off-Label Uses

Some doctors may prescribe Ibrutinib off-label for conditions like diffuse large B-cell lymphoma (DLBCL), central nervous system lymphoma, or post-transplant lymphoproliferative disorder. Off-label use is based on clinical evidence and your doctor's judgment.

How Is Ibrutinib Taken?

Ibrutinib is taken once daily by mouth, at approximately the same time each day. It comes in several forms:

• Capsules: 70 mg, 140 mg
• Tablets: 140 mg, 280 mg, 420 mg, 560 mg
• Oral suspension: 70 mg/mL (for patients who have difficulty swallowing)

Typical Dosing

• CLL/SLL: 420 mg once daily
• Waldenström's macroglobulinemia: 420 mg once daily
• Chronic graft-versus-host disease: 420 mg once daily

Your doctor may reduce your dose to 280 mg or 140 mg daily if you experience significant side effects or are taking certain medications that interact with Ibrutinib.

Important Instructions

• Swallow capsules or tablets whole with a glass of water
• Do not open, break, or chew capsules
• Do not cut, crush, or chew tablets
• Can be taken with or without food
• Avoid grapefruit, Seville oranges, and starfruit — these can increase Ibrutinib levels in your blood and raise the risk of side effects

If you miss a dose, take it as soon as you remember on the same day. If it's already the next day, skip the missed dose and take your next dose at the regular time. Do not double up.

Who Should Not Take Ibrutinib?

Ibrutinib is not right for everyone. You should not take Ibrutinib if you:

• Have a known allergy to ibrutinib or any of its ingredients
• Have severe liver impairment (Child-Pugh class C)
• Are pregnant or planning to become pregnant — Ibrutinib can cause harm to an unborn baby
• Are breastfeeding — it is not known if Ibrutinib passes into breast milk

Use caution and talk to your doctor if you:

• Take blood thinners or antiplatelet medications (increased bleeding risk)
• Take strong CYP3A4 inhibitors like Ketoconazole, Itraconazole, or Clarithromycin (these dramatically increase Ibrutinib levels)
• Have a history of heart problems, especially atrial fibrillation
• Have liver or kidney problems
• Are scheduled for surgery — you may need to stop Ibrutinib 3-7 days before and after a procedure due to bleeding risk

For a complete list of interactions, see our guide on Ibrutinib drug interactions.

How Much Does Ibrutinib Cost?

Ibrutinib is one of the more expensive cancer medications on the market:

• Cash price: approximately $14,000 to $18,000 per 30-day supply, depending on the dose and pharmacy
• Medicare Part D (2026): negotiated price of $9,319 per 30-day supply under the Inflation Reduction Act — 38% below the 2023 list price. Medicare Part D patients benefit from the $2,000 annual out-of-pocket cap
• Commercial insurance: copays vary widely but can be hundreds or thousands per month without assistance

Ways to Save

• Imbruvica By Your Side Copay Card: commercially insured patients may pay as little as $0. Not available for Medicare, Medicaid, or Tricare patients
• Patient assistance programs: Janssen/AbbVie offer free Ibrutinib for uninsured or underinsured patients who meet income requirements
• Nonprofit copay assistance: the Leukemia & Lymphoma Society, PAN Foundation, and CancerCare offer copay help for qualifying patients

A generic version of Ibrutinib is not yet available in the U.S. as of early 2026, though patents are expected to expire around 2027 and six generic applications are pending. Generic launch could happen in 2026-2027, which would significantly lower costs.

For more details, read our full guide on saving money on Ibrutinib.

Final Thoughts

Ibrutinib has transformed the treatment of CLL, SLL, WM, and cGVHD since its approval in 2013. As a once-daily oral medication, it offers a more manageable treatment experience than traditional chemotherapy for many patients.

If you've been prescribed Ibrutinib and need help finding it or affording it, Medfinder can help you check pharmacy availability and connect with savings resources. For information on side effects, see our guide on Ibrutinib side effects.